US4853221A
(en)
|
1980-11-13 |
1989-08-01 |
Warner-Lambert Company |
Method for treating non-small cell lung cancer, head and neck cancers and breast cancer
|
US4801575A
(en)
|
1986-07-30 |
1989-01-31 |
The Regents Of The University Of California |
Chimeric peptides for neuropeptide delivery through the blood-brain barrier
|
US5294430A
(en)
|
1988-09-12 |
1994-03-15 |
University Of Rochester |
Use of dithiocarbamates to treat myelosuppression
|
US5035878A
(en)
|
1988-09-12 |
1991-07-30 |
University Of Rochester |
Use of dithiocarbamates to counteract myelosuppression
|
US5542935A
(en)
|
1989-12-22 |
1996-08-06 |
Imarx Pharmaceutical Corp. |
Therapeutic delivery systems related applications
|
US5597798A
(en)
|
1990-03-05 |
1997-01-28 |
The Regents Of The University Of California |
Taxol and epidermal growth factor used to enhance treatment of ovarian cancer
|
DE69232852T2
(de)
|
1991-02-21 |
2003-09-04 |
Smithkline Beecham Corp., Philadelphia |
Verwendung von topotecan in der behandlung von nichtkleinzelligen lungenkarzinomen
|
US6287792B1
(en)
|
1991-06-17 |
2001-09-11 |
The Regents Of The University Of California |
Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
|
US5795870A
(en)
|
1991-12-13 |
1998-08-18 |
Trustees Of Princeton University |
Compositions and methods for cell transformation
|
US5795871A
(en)
|
1994-04-26 |
1998-08-18 |
Nobuhiro Narita |
Pharmaceutical composition for treatment of non-small cell lung cancer
|
US6011069A
(en)
|
1995-12-26 |
2000-01-04 |
Nisshin Flour Milling Co., Ltd. |
Multidrug resistance inhibitors
|
US5998402A
(en)
|
1996-04-19 |
1999-12-07 |
American Home Products Corporation |
2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
|
EP0983389A1
(en)
|
1997-06-04 |
2000-03-08 |
Rijksuniversiteit te Leiden |
A diagnostic test kit for determining a predisposition for breast and ovarian cancer, materials and methods for such determination
|
US6335156B1
(en)
|
1997-12-18 |
2002-01-01 |
The Johns Hopkins University School Of Medicine |
14-3-3σ arrests the cell cycle
|
CA2319495A1
(en)
|
1998-06-08 |
1999-12-16 |
Advanced Medicine, Inc. |
Multibinding inhibitors of microsomal triglyceride transferase protein
|
EP1104297B8
(en)
|
1998-07-09 |
2006-05-03 |
Cephalon, Inc. |
Compositions for the treatment of chronic lymphocytic leukemia
|
AU6607100A
(en)
|
1999-07-23 |
2001-02-13 |
Regents Of The University Of California, The |
Anti-growth factor receptor avidin fusion proteins as universal vectors for drugdelivery
|
US6635677B2
(en)
|
1999-08-13 |
2003-10-21 |
Case Western Reserve University |
Methoxyamine combinations in the treatment of cancer
|
US6372250B1
(en)
|
2000-04-25 |
2002-04-16 |
The Regents Of The University Of California |
Non-invasive gene targeting to the brain
|
US20020037328A1
(en)
*
|
2000-06-01 |
2002-03-28 |
Brown Dennis M. |
Hexitol compositions and uses thereof
|
GB0014820D0
(en)
|
2000-06-16 |
2000-08-09 |
Medical Res Council |
Methods and materials relating to plasmid vectors
|
ITMI20002358A1
(it)
|
2000-10-31 |
2002-05-01 |
Flavio Moroni |
Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
|
US7619005B2
(en)
|
2000-11-01 |
2009-11-17 |
Cognition Pharmaceuticals Llc |
Methods for treating cognitive impairment in humans with Multiple Sclerosis
|
EP1410013A4
(en)
|
2001-06-21 |
2006-02-01 |
Millennium Pharm Inc |
COMPOSITIONS, NEEDS AND METHODS FOR THE IDENTIFICATION, EVALUATION, PREVENTION AND TREATMENT OF BREAST CANCERS AND OVARIA
|
DE60329126D1
(de)
|
2002-02-20 |
2009-10-15 |
Beth Israel Hospital |
Konjugate mit biologisch abbaubarem polymer und verwendung dafür
|
JP4694786B2
(ja)
|
2002-03-01 |
2011-06-08 |
ロジャー・ウィリアムズ・ホスピタル |
乳房、前立腺および卵巣の癌の予測のための、Shcタンパク質に関連する方法および組成物
|
JP2005529101A
(ja)
|
2002-04-11 |
2005-09-29 |
ザイモジェネティクス インコーポレイティッド |
卵巣癌を治療するためのインターロイキン−19の使用法
|
WO2003087308A2
(en)
|
2002-04-11 |
2003-10-23 |
Zymogenetics, Inc. |
Use of interleukin-24 to treat ovarian cancer
|
US7101576B2
(en)
|
2002-04-12 |
2006-09-05 |
Elan Pharma International Limited |
Nanoparticulate megestrol formulations
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US7388079B2
(en)
|
2002-11-27 |
2008-06-17 |
The Regents Of The University Of California |
Delivery of pharmaceutical agents via the human insulin receptor
|
WO2004064748A2
(en)
|
2003-01-21 |
2004-08-05 |
Trustees Of Dartmouth College |
Compositions and methods for treatment of ovarian cancer
|
EP1620120A4
(en)
|
2003-03-24 |
2010-01-06 |
Sequoia Pharmaceuticals Inc |
BIOLOGICAL ACTIVE CONJUGATES WITH LONG-TERM EFFECT
|
ZA200507752B
(en)
|
2003-03-28 |
2007-01-31 |
Threshold Pharmaceuticals Inc |
Compositions and methods for treating cancer
|
ES2770035T3
(es)
|
2003-04-11 |
2020-06-30 |
Ptc Therapeutics Inc |
Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
|
BRPI0414136A
(pt)
|
2003-09-04 |
2006-10-31 |
Aventis Pharma Inc |
indóis substituìdos como inibidores de poli(adp-ribose) polimerase (parp)
|
US7446122B2
(en)
|
2003-10-02 |
2008-11-04 |
Cephalon, Inc. |
Substituted indole derivatives
|
HUP0303313A2
(hu)
|
2003-10-09 |
2005-07-28 |
Richter Gedeon Vegyészeti Gyár Rt. |
Transzdermális gyógyszerkészítmények
|
CA2545942C
(en)
|
2003-11-14 |
2012-07-10 |
Lorus Therapeutics Inc. |
Aryl imidazoles and their use as anti-cancer agents
|
KR101130556B1
(ko)
|
2004-03-11 |
2012-03-30 |
4에스체 악티엔게젤샤프트 |
Hdac 억제제로서의 설포닐피롤
|
WO2005099824A1
(en)
|
2004-03-30 |
2005-10-27 |
Synta Pharmaceuticals, Corp. |
1-glyoxylamide indolizines for treating lung and ovarian cancer
|
WO2005098446A2
(en)
|
2004-03-31 |
2005-10-20 |
The Johns Hopkins University |
Biomarkers for ovarian cancer
|
US7754897B2
(en)
|
2005-06-15 |
2010-07-13 |
Cardiome Pharma Corp. |
Synthetic processes for the preparation of aminocyclohexyl ether compounds
|
US8957056B2
(en)
|
2004-05-25 |
2015-02-17 |
Sloan-Kettering Instiute For Cancer Research |
Migrastatin analogs in the treatment of cancer
|
NZ551680A
(en)
|
2004-06-30 |
2010-02-26 |
Janssen Pharmaceutica Nv |
Quinazolinone derivatives as PARP inhibitors
|
EP1978032A3
(en)
|
2004-07-22 |
2009-02-18 |
Erasmus University Medical Center Rotterdam |
Binding molecules
|
PT1786430E
(pt)
|
2004-08-20 |
2013-06-04 |
Buck Inst For Age Res |
Pequenas moléculas que substituam ou agonizam a função p53
|
ES2322175T3
(es)
|
2004-09-17 |
2009-06-17 |
EISAI R&D MANAGEMENT CO., LTD. |
Composicion medicinal con estabilidad mejorada y gelificacion reducida.
|
US8080675B2
(en)
|
2004-09-21 |
2011-12-20 |
Marshall Edwards, Inc. |
Chroman derivatives, medicaments and use in therapy
|
EP1824821A2
(en)
|
2004-11-23 |
2007-08-29 |
PTC Therapeutics, Inc. |
Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
|
EP1827437B1
(en)
|
2004-12-15 |
2011-11-02 |
Novartis AG |
Combinations of therapeutic agents for treating cancer
|
AU2006206512B2
(en)
|
2005-01-19 |
2012-09-13 |
Eisai Inc. |
Diazabenzo(de)anthracen-3-one compounds and methods for inhibiting PARP
|
US8404829B2
(en)
|
2005-01-25 |
2013-03-26 |
The Regents Of The University Of California |
Predictive and therapeutic markers in ovarian cancer
|
EP1702989A1
(en)
|
2005-03-16 |
2006-09-20 |
Fundacion para la Investigacion Clinica y Molecular del Cancer de Pulmon |
Method of predicting the clinical response to cisplatin or carboplatin chemotherapeutic treatment
|
US7728026B2
(en)
|
2005-04-11 |
2010-06-01 |
Abbott Laboratories, Inc. |
2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
|
MX2007013304A
(es)
|
2005-04-26 |
2007-12-13 |
Pfizer |
Anticuerpos de p-caderina.
|
AR053272A1
(es)
|
2005-05-11 |
2007-04-25 |
Hoffmann La Roche |
Determinacion de responsivos a la quimioterapia
|
CA2611173C
(en)
|
2005-06-24 |
2019-11-12 |
Ciphergen Biosystems, Inc. |
Biomarkers for ovarian cancer
|
MX2008000745A
(es)
*
|
2005-07-15 |
2008-03-14 |
Schering Corp |
Derivados de quinazolina utiles en el tratamiento del cancer.
|
US8133692B2
(en)
|
2005-07-20 |
2012-03-13 |
University Of South Florida |
Methods of predicting responsiveness to chemotherapeutic agents and selecting treatments
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
WO2007021966A1
(en)
|
2005-08-12 |
2007-02-22 |
Synta Pharmaceuticals Corp. |
Pyrazole compounds that modulate hsp90 activity
|
US8124095B2
(en)
|
2005-10-07 |
2012-02-28 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of erythropoietin to the CNS
|
US7507536B2
(en)
|
2005-10-07 |
2009-03-24 |
The Johns Hopkins University |
Methylation markers for diagnosis and treatment of ovarian cancer
|
KR20080066039A
(ko)
|
2005-10-19 |
2008-07-15 |
추가이 세이야쿠 가부시키가이샤 |
신규 수용성 프로드러그를 함유하는 췌장암, 난소암 또는 간암의 예방 또는 치료제
|
US20090099102A1
(en)
|
2005-10-27 |
2009-04-16 |
The Brigham And Women's Hospital, Inc. |
Ginkgolides in the Treatment and Prevention of Ovarian Cancer
|
EP1948179A1
(en)
|
2005-11-11 |
2008-07-30 |
Boehringer Ingelheim International GmbH |
Quinazoline derivatives for the treatment of cancer diseases
|
CA2630175C
(en)
|
2005-11-16 |
2018-10-23 |
Pantarhei Bioscience B.V. |
Immunotherapeutic method for treating and/or preventing ovarian cancer
|
JP5294874B2
(ja)
|
2005-12-20 |
2013-09-18 |
インサイト・コーポレイション |
インドールアミン2,3−ジオキシゲナーゼのモジュレーターとしてのn−ヒドロキシアミジノヘテロ環
|
CN101389632B
(zh)
|
2005-12-23 |
2013-02-06 |
生态生物有限公司 |
螺缩酮
|
WO2007091241A1
(en)
|
2006-02-10 |
2007-08-16 |
Ramot At Tel Aviv University Ltd. |
Treatment of ovarian cancer
|
CN101448843B
(zh)
|
2006-03-17 |
2012-05-09 |
埃姆比特生物科学公司 |
用于疾病治疗的咪唑并噻唑化合物
|
NZ572812A
(en)
|
2006-04-26 |
2010-09-30 |
Hoffmann La Roche |
THIENO [3, 2-D] PYRIMIDINE Indazole DERIVATIVE USEFUL AS PI3K INHIBITOR
|
IL282783B2
(en)
|
2006-05-18 |
2023-09-01 |
Caris Mpi Inc |
A system and method for determining a personalized medical intervention for a disease stage
|
US8768629B2
(en)
|
2009-02-11 |
2014-07-01 |
Caris Mpi, Inc. |
Molecular profiling of tumors
|
AU2007267847B2
(en)
|
2006-05-25 |
2012-04-12 |
Synta Pharmaceuticals Corp. |
Triazole compounds that modulate Hsp90 activity
|
WO2007139951A2
(en)
|
2006-05-25 |
2007-12-06 |
Synta Pharmaceuticals Corp. |
Method for treating proliferative disorders associated with protooncogene products
|
EP2069351B1
(en)
|
2006-06-20 |
2015-10-28 |
AbbVie Inc. |
Pyrazoloquinazolinones as parp inhibitors
|
JP5399905B2
(ja)
|
2006-09-01 |
2014-01-29 |
センワ バイオサイエンシズ インコーポレイテッド |
セリン−トレオニンタンパク質キナーゼおよびparp調節因子
|
US7547781B2
(en)
|
2006-09-11 |
2009-06-16 |
Curis, Inc. |
Quinazoline based EGFR inhibitors containing a zinc binding moiety
|
US8277807B2
(en)
|
2006-10-12 |
2012-10-02 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
UY30639A1
(es)
|
2006-10-17 |
2008-05-31 |
Kudos Pharm Ltd |
Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
|
US8247421B2
(en)
|
2006-12-21 |
2012-08-21 |
Vertex Pharmaceuticals Incorporated |
5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors
|
UY30892A1
(es)
|
2007-02-07 |
2008-09-02 |
Smithkline Beckman Corp |
Inhibidores de la actividad akt
|
US8168415B2
(en)
|
2007-02-07 |
2012-05-01 |
The Regents Of The University Of Colorado |
Axl fusion proteins as Axl tyrosine kinase inhibitors
|
PL2129396T3
(pl)
|
2007-02-16 |
2014-02-28 |
Merrimack Pharmaceuticals Inc |
Przeciwciała przeciw ERBB3 i ich zastosowania
|
KR20090115879A
(ko)
|
2007-02-28 |
2009-11-09 |
이노텍 파마슈티컬스 코포레이션 |
인데노이소퀴놀리논 유사체와 이의 이용 방법
|
AU2008223069B2
(en)
|
2007-03-02 |
2012-12-13 |
F. Hoffmann-La Roche Ag |
Predicting response to a HER dimerisation inhibitor based on low HER3 expression
|
WO2008107478A1
(en)
|
2007-03-08 |
2008-09-12 |
Janssen Pharmaceutica Nv |
Quinolinone derivatives as parp and tank inhibitors
|
US8030060B2
(en)
|
2007-03-22 |
2011-10-04 |
West Virginia University |
Gene signature for diagnosis and prognosis of breast cancer and ovarian cancer
|
PA8775801A1
(es)
|
2007-04-06 |
2009-05-15 |
Neurocrine Biosciences Inc |
Antagonista del receptor de la hormona liberadora de gonadotropina y procedimientos relacionados con los mismos
|
TWI448284B
(zh)
|
2007-04-24 |
2014-08-11 |
Theravance Inc |
雙效抗高血壓劑
|
JP2008295328A
(ja)
|
2007-05-30 |
2008-12-11 |
Fujifilm Corp |
卵巣癌の検出方法、及び抑制方法
|
CA2687754C
(en)
|
2007-06-08 |
2015-12-08 |
Janssen Pharmaceutica N.V. |
Piperidine, piperazine derivatives for use as dgat inhibitors
|
WO2009006439A1
(en)
|
2007-06-29 |
2009-01-08 |
Correlogic Systems, Inc. |
Predictive markers for ovarian cancer
|
WO2009016565A1
(en)
|
2007-07-27 |
2009-02-05 |
Piramal Life Sciences Limited |
Tricyclic compounds for the treatment of inflammatory disorders
|
SA08290475B1
(ar)
|
2007-08-02 |
2013-06-22 |
Targacept Inc |
(2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
|
US7442830B1
(en)
|
2007-08-06 |
2008-10-28 |
Millenium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
AU2008287831B2
(en)
|
2007-08-10 |
2013-05-23 |
Mitsubishi Tanabe Pharma Corporation |
Novel salt of isoquinoline compound and crystal thereof
|
EP2193210B1
(en)
|
2007-09-17 |
2014-11-12 |
Koninklijke Philips N.V. |
Method for the analysis of ovarian cancer disorders
|
EP2842956A1
(en)
|
2007-10-03 |
2015-03-04 |
Eisai Inc. |
PARP inhibitor compounds, compositions and methods of use
|
JO2778B1
(en)
|
2007-10-16 |
2014-03-15 |
ايساي انك |
Certain vehicles, installations and methods
|
CN101909630A
(zh)
|
2007-11-02 |
2010-12-08 |
新加坡科技研究局 |
预防和治疗肿瘤的方法和化合物
|
IL187247A0
(en)
|
2007-11-08 |
2008-12-29 |
Hadasit Med Res Service |
Novel synthetic analogs of sphingolipids
|
US20090123419A1
(en)
|
2007-11-12 |
2009-05-14 |
Bipar Sciences |
Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
|
US20090170842A1
(en)
|
2007-11-14 |
2009-07-02 |
University Of Kansas |
Brca1-based breast or ovarian cancer prevention agents and methods of use
|
JP5758630B2
(ja)
|
2007-11-15 |
2015-08-05 |
エンメエッセディ・イタリア・エッセ・エッレ・エッレ |
Parp阻害剤としてのピリダジノン誘導体
|
WO2009065230A1
(en)
|
2007-11-23 |
2009-05-28 |
British Columbia Cancer Agency Branch |
Methods for detecting lung cancer and monitoring treatment response
|
CA3017076A1
(en)
|
2007-12-05 |
2009-06-18 |
The Wistar Institute Of Anatomy And Biology |
Method for diagnosing lung cancers using gene expression profiles in peripheral blood mononuclear cells
|
US8933212B2
(en)
|
2007-12-06 |
2015-01-13 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Use of protease nexin 1 inhibitors to reduce metastasis
|
US8741889B2
(en)
|
2008-01-11 |
2014-06-03 |
Hoffmann-La Roche Inc |
Method of treating non-small cell lung cancer and colon cancer with gamma-secretase inhibitor
|
CN101981037B
(zh)
|
2008-01-30 |
2013-09-04 |
吉宁特有限公司 |
吡唑并嘧啶pi3k抑制剂化合物及使用方法
|
WO2009099561A2
(en)
|
2008-01-31 |
2009-08-13 |
The Brigham And Womens' Hospital, Inc. |
Urinary ca125 peptides as biomarkers of ovarian cancer
|
WO2009099736A2
(en)
|
2008-02-06 |
2009-08-13 |
Lead Therapeutics, Inc. |
Benzoxazole carboxamide inhibitors of poly(adp-ribose)polymerase (parp)
|
US20090275519A1
(en)
|
2008-02-08 |
2009-11-05 |
Aileron Therapeutics, Inc. |
Therapeutic peptidomimetic macrocycles
|
EP2247755B1
(en)
|
2008-02-14 |
2015-01-28 |
Decode Genetics EHF |
Susceptibility variants for lung cancer
|
WO2009104149A1
(en)
|
2008-02-20 |
2009-08-27 |
Actelion Pharmaceuticals Ltd |
Combination comprising paclitaxel for treating ovarian cancer
|
FR2928151B1
(fr)
|
2008-03-03 |
2010-12-31 |
Sanofi Aventis |
Derives platine-carbene n-heterocyclique, leur preparation et leur application en therapeutique
|
SI2268623T1
(sl)
|
2008-03-17 |
2016-01-29 |
Ambit Biosciences Corporation |
Derivati kinazolina kot modulatorji raf-kinaze in postopki uporabe le-teh
|
US8476026B2
(en)
|
2008-04-01 |
2013-07-02 |
The Brigham And Women's Hospital, Inc. |
Biomarkers of ovarian cancer
|
EP2291349A2
(en)
|
2008-04-14 |
2011-03-09 |
The Board of Regents of The University of Texas System |
Small molecule inhibitors of the pleckstrin homology domain and methods for using same
|
EP2265286B1
(en)
|
2008-04-16 |
2016-06-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment, the prognostic assessment and the staging of non-small cell lung cancer
|
CL2009001152A1
(es)
|
2008-05-13 |
2009-10-16 |
Array Biopharma Inc |
Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
|
EP2288741B1
(en)
|
2008-05-14 |
2015-01-28 |
University Health Network |
Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
|
CN104059066A
(zh)
|
2008-06-11 |
2014-09-24 |
健泰科生物技术公司 |
二氮杂咔唑和使用方法
|
JP5613156B2
(ja)
|
2008-07-09 |
2014-10-22 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
Axl阻害剤として有用な架橋二環ヘテロアリール置換トリアゾール
|
US8946239B2
(en)
|
2008-07-10 |
2015-02-03 |
Duquesne University Of The Holy Spirit |
Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
|
US8338477B2
(en)
|
2008-07-11 |
2012-12-25 |
Neumedics |
Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits
|
ES2466565T3
(es)
|
2008-08-06 |
2014-06-10 |
Biomarin Pharmaceutical Inc. |
Inhibidores dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP)
|
EP2323737A2
(en)
|
2008-08-08 |
2011-05-25 |
Synta Pharmaceuticals Corp. |
Triazole compounds that modulate hsp90 activity
|
BRPI0917871A2
(pt)
|
2008-08-15 |
2017-06-20 |
Merrimack Pharmaceuticals Inc |
agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico
|
GEP20135785B
(en)
|
2008-08-22 |
2013-03-11 |
Novartis Ag |
Pyrrolopyrimidine compounds as cdk inhibitors
|
EP2166008A1
(en)
|
2008-09-23 |
2010-03-24 |
Genkyo Tex Sa |
Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
|
KR100961410B1
(ko)
|
2008-10-14 |
2010-06-09 |
(주)네오팜 |
단백질 키나제 억제제로서 헤테로사이클릭 화합물
|
GB0819095D0
(en)
|
2008-10-17 |
2008-11-26 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
EP2350664B1
(en)
|
2008-10-21 |
2021-05-19 |
ImmunoGenesis, Inc. |
Treatment of cancer using the hypoxia activated prodrug th-302 in combination with docetaxel or pemetrexed
|
WO2010059858A1
(en)
|
2008-11-19 |
2010-05-27 |
Duke University |
Manassantin compounds and methods of making and using same
|
JP5108153B2
(ja)
|
2008-11-26 |
2012-12-26 |
ファイザー・インク |
ケモカイン受容体モジュレーターとしての3−アミノシクロペンタンカルボキサミド
|
US20100160322A1
(en)
|
2008-12-04 |
2010-06-24 |
Abbott Laboratories |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
US8058075B2
(en)
|
2008-12-10 |
2011-11-15 |
University Of Utah Research Foundation |
Molecular fluorescence sensor for highly sensitive and selective detection of mercury
|
WO2010072383A1
(en)
|
2008-12-22 |
2010-07-01 |
7Roche Diagnostics Gmbh |
Armet as a marker for cancer
|
MX2011007741A
(es)
|
2009-01-23 |
2011-09-06 |
Takeda Pharmaceutical |
Inhibidores de poli(adenosina difosfato plaquetaria (adp)-ribosa) polimerasa poli adenosina difosfato plaquetaria ribosa (parp).
|
US8492361B2
(en)
|
2009-02-10 |
2013-07-23 |
Celgene Corporation |
Methods for treating non-small cell lung cancer using 5-azacytidine
|
US8648046B2
(en)
|
2009-02-26 |
2014-02-11 |
Oncolix, Inc. |
Compositions and methods for visualizing and eliminating cancer stem cells
|
TWI476192B
(zh)
|
2009-02-27 |
2015-03-11 |
Ambit Biosciences Corp |
Jak激酶調節化合物及其使用方法
|
US8969001B2
(en)
|
2009-03-12 |
2015-03-03 |
Rush University Medical Center |
Materials and methods for predicting recurrence of non-small cell lung cancer
|
CN101869558A
(zh)
*
|
2009-04-22 |
2010-10-27 |
北京大学 |
二乙酰二脱水卫矛醇的抗血管生成及肿瘤转移作用
|
PT104607B
(pt)
|
2009-05-20 |
2012-03-23 |
Univ De Coimbra |
Derivados triterpenóides úteis como agentes antiproliferativos
|
EP3045457B1
(en)
|
2009-06-15 |
2018-05-09 |
Nerviano Medical Sciences S.r.l. |
Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
|
US8980268B2
(en)
|
2009-07-29 |
2015-03-17 |
Regeneron Pharamceuticals, Inc. |
Methods for treating cancer by administering an anti-Ang-2 antibody
|
EP2459561A1
(en)
|
2009-07-30 |
2012-06-06 |
Takeda Pharmaceutical Company Limited |
Poly (adp-ribose) polymerase (parp) inhibitors
|
WO2011014697A1
(en)
|
2009-07-31 |
2011-02-03 |
The Translational Genomics Research Institute |
Methods of assessing a risk of cancer progression
|
EP2471791B1
(en)
|
2009-08-26 |
2014-11-12 |
Takeda Pharmaceutical Company Limited |
Fused heterocyclic ring derivative and use thereof
|
US20130203861A1
(en)
|
2009-09-09 |
2013-08-08 |
Golden Biotechnology Corporation |
Methods and compositions for treating ovarian cancer
|
WO2011038139A1
(en)
|
2009-09-23 |
2011-03-31 |
Amgen Inc. |
Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
|
AU2010299820A1
(en)
|
2009-09-28 |
2012-04-19 |
F. Hoffmann-La Roche Ag |
Benzoxepin PI3K inhibitor compounds and methods of use
|
AU2010303324A1
(en)
|
2009-10-08 |
2012-04-05 |
Sanford-Burnham Medical Research Institute |
Apogossypolone derivatives as anticancer agents
|
EP2486002B1
(en)
|
2009-10-09 |
2019-03-27 |
Oryzon Genomics, S.A. |
Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
|
EP2523664A4
(en)
|
2010-01-13 |
2013-06-26 |
Tempero Pharmaceuticals Inc |
COMPOUNDS AND METHODS
|
SA111320200B1
(ar)
|
2010-02-17 |
2014-02-16 |
ديبيوفارم اس ايه |
مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
|
CN102933604B
(zh)
|
2010-02-23 |
2016-04-06 |
赛诺菲 |
抗-α2整联蛋白抗体及其用途
|
EP2548017A2
(en)
|
2010-03-15 |
2013-01-23 |
Genus Oncology, Llc |
Small molecule inhibitors of muc1 and methods of identifying the same
|
US8927538B2
(en)
|
2010-03-22 |
2015-01-06 |
Council Of Scientific & Industrial Research |
Carbazole linked pyrrolo[2,1-c][1,4]benzodiazefine hybrids as potential anticancer agents and process for the preparation thereof
|
CN102947322B
(zh)
|
2010-04-27 |
2016-09-07 |
法马马有限公司 |
在7(8)位不饱和的抗癌甾体内酯
|
WO2011138409A1
(en)
|
2010-05-05 |
2011-11-10 |
Universität Bayreuth |
Combretastatin analogs for use in the treatment of cancer
|
CN103003424B
(zh)
|
2010-05-18 |
2015-05-13 |
株式会社医学生物学研究所 |
结合转化生长因子α且对Ras基因突变的癌具有增殖抑制活性的抗体
|
KR101852169B1
(ko)
|
2010-05-20 |
2018-04-26 |
어레이 바이오파마 인크. |
Trk 키나제 저해제로서의 매크로시클릭 화합물
|
HUE032515T2
(en)
|
2010-06-23 |
2017-09-28 |
Hanmi Science Co Ltd |
New condensed pyrimidine derivatives for inhibiting tyrosine kinase activity
|
US8962679B2
(en)
|
2010-07-08 |
2015-02-24 |
The Administrators Of The Tulane Educational Fund |
Daidzein analogs as treatment for cancer
|
WO2012007345A2
(en)
|
2010-07-12 |
2012-01-19 |
Bayer Pharma Aktiengesellschaft |
Substituted imidazo[1,2-a]pyrimidines and -pyridines
|
GB201012105D0
(en)
|
2010-07-19 |
2010-09-01 |
Domainex Ltd |
Novel pyrimidine compounds
|
US20120171694A1
(en)
|
2010-07-30 |
2012-07-05 |
Vermillion, Inc. |
Predictive markers and biomarker panels for ovarian cancer
|
KR101434841B1
(ko)
|
2010-08-05 |
2014-08-29 |
템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 |
2-치환-8-알킬-7-옥소-7,8-디하이드로피리도[2,3-d] 피리미딘-6-카르보니트릴 및 이의 용도
|
JP2013537552A
(ja)
*
|
2010-08-18 |
2013-10-03 |
デル マー ファーマスーティカルズ |
ジアンヒドロガラクチトール及びジアセチルジアンヒドロガラクチトール等の置換ヘキシトールを含む準最適に投与された化合物の治療的有効性を改良するための組成物及び方法
|
US8471026B2
(en)
|
2010-08-26 |
2013-06-25 |
Millennium Pharmaceuticals, Inc. |
Substituted hydroxamic acids and uses thereof
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
US8575191B2
(en)
|
2010-09-01 |
2013-11-05 |
Arqule, Inc. |
Methods for treatment of non-small cell lung cancer
|
KR101864908B1
(ko)
|
2010-09-01 |
2018-06-05 |
질레드 코네티컷 인코포레이티드 |
피리다지논, 그의 제조 방법 및 사용 방법
|
WO2012037573A1
(en)
|
2010-09-17 |
2012-03-22 |
Indiana University Research And Technology Corporation |
Small molecule inhibitors of replication protein a that also act synergistically with cisplatin
|
US8927562B2
(en)
|
2010-09-28 |
2015-01-06 |
Merck Sharp & Dohme Corp. |
Fused tricyclic inhibitors of mammalian target of rapamycin
|
KR101497113B1
(ko)
|
2010-10-20 |
2015-03-03 |
한국생명공학연구원 |
Hif-1 활성을 저해하는 아릴옥시페녹시아크릴계 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
|
CN103201260B
(zh)
|
2010-11-11 |
2015-05-27 |
莱德克斯制药有限公司 |
药物衍生物
|
JP2013542263A
(ja)
|
2010-11-12 |
2013-11-21 |
エンドサイト・インコーポレイテッド |
癌を処置する方法
|
UY33740A
(es)
|
2010-11-18 |
2012-05-31 |
Takeda Pharmaceutical |
Método para tratar el cáncer de mama y cáncer de ovarios
|
WO2012075362A2
(en)
|
2010-12-03 |
2012-06-07 |
Emory University |
Chemokine cxcr4 receptor modulators and used related thereto
|
EP2649078B1
(en)
|
2010-12-06 |
2016-07-27 |
Council of Scientific & Industrial Research |
4-aza-2, 3-didehydropodophyllotoxin compounds and process for the preparation thereof
|
AR084312A1
(es)
|
2010-12-16 |
2013-05-08 |
Genentech Inc |
Compuestos triciclicos inhibidores de la pi3k y composiciones farmaceuticas
|
WO2012079128A1
(en)
|
2010-12-17 |
2012-06-21 |
Des R Richardson |
Thiosemicarbazone compounds and use in the treatment of cancer
|
WO2012096832A2
(en)
|
2011-01-12 |
2012-07-19 |
Crystal Biopharmaceutical Llc |
Hdac inhibiting derivatives of camptothecin
|
BR112013018515B1
(pt)
|
2011-01-26 |
2021-06-29 |
Nerviano Medical Sciences S.R.I |
Derivados de pirrol tricíclico, processo para sua preparação e seu uso como inibidores da quinase
|
US8946409B2
(en)
|
2011-01-27 |
2015-02-03 |
Board Of Regents, The University Of Texas System |
Polycyclic β lactam derivatives for the treatment of cancer
|
PL2670753T3
(pl)
|
2011-01-31 |
2017-05-31 |
Novartis Ag |
Nowe pochodne heterocykliczne
|
KR20140024860A
(ko)
|
2011-02-24 |
2014-03-03 |
버밀리언, 인코포레이티드 |
난소암에 대한 바이오마커 패널,진단 방법 및 시험 키트
|
BR112013020975A2
(pt)
|
2011-02-24 |
2016-10-11 |
Jiangsu Hansoh Pharmaceutical Co Ltd |
compostos contendo fósforo como inibidores de proteína quinases
|
WO2012116328A2
(en)
|
2011-02-24 |
2012-08-30 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Bad phosphorylation determines ovarian cancer chemo-sensitivity and patient survival
|
EP3323820B1
(en)
|
2011-02-28 |
2023-05-10 |
Epizyme, Inc. |
Substituted 6,5-fused bicyclic heteroaryl compounds
|
LT3447061T
(lt)
|
2011-03-01 |
2022-01-25 |
NuCana plc |
Farmacinė vaisto forma, apimanti 5-fluor-2'-deoksiuridinofosforamidato darinį, skirtą naudoti vėžio gydymui
|
EP2681552A2
(en)
|
2011-03-02 |
2014-01-08 |
Nestec S.A. |
Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
|
ES2586411T3
(es)
|
2011-03-04 |
2016-10-14 |
New York University |
Macrociclos sustitutos de enlace de hidrógeno como moduladores de Ras
|
US8748470B2
(en)
|
2011-03-17 |
2014-06-10 |
The University Of Chicago |
Methods for treating ovarian cancer by inhibiting fatty acid binding proteins
|
US20140357605A1
(en)
|
2012-03-22 |
2014-12-04 |
Bristol-Myers Squibb Company |
Bis(fluoroalkyl)-1,4-benzodiazepinone compounds
|
WO2012138537A1
(en)
|
2011-04-01 |
2012-10-11 |
Immunogen, Inc. |
Compositions and methods for treatment of ovarian, peritoneal, and fallopian tube cancer
|
EP2693880A1
(en)
|
2011-04-04 |
2014-02-12 |
Merck Sharp & Dohme Corp. |
Gamma secretase inhibitors
|
CN103748093B
(zh)
|
2011-06-24 |
2016-06-01 |
艾科尔公司 |
被取代的咪唑并吡啶基-氨基吡啶化合物
|
SI2736895T1
(sl)
|
2011-07-27 |
2016-03-31 |
Astrazeneca Ab |
Derivati 2-(2,4,5-substituiranega-anilino) pirimidina, kot modulatorji EGFR uporabni za zdravljenje raka
|
US9499530B2
(en)
|
2011-08-01 |
2016-11-22 |
Hangzhou Minsheng Institutes For Pharma Research |
Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament
|
CN103958502B
(zh)
|
2011-08-04 |
2016-02-10 |
阵列生物制药公司 |
作为丝氨酸/苏氨酸激酶抑制剂的喹唑啉化合物
|
WO2013020285A1
(zh)
|
2011-08-10 |
2013-02-14 |
Yang Zhen |
化学合成安卓幸的方法及其抑制非小细胞肺癌的应用
|
DE102011112978A1
(de)
|
2011-09-09 |
2013-03-14 |
Merck Patent Gmbh |
Benzonitrilderivate
|
CN103732577B
(zh)
|
2011-09-19 |
2017-04-05 |
希格马托制药工业公司 |
作为有效hdac抑制剂的携带内酰胺的硫代衍生物和它们作为药物的用途
|
WO2013043255A1
(en)
|
2011-09-21 |
2013-03-28 |
University Of South Alabama |
Methods and compositions for the treatment of ovarian cancer
|
JP6014149B2
(ja)
|
2011-09-22 |
2016-10-25 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
ヤヌスキナーゼ阻害剤としての非環式シアノエチルピラゾール
|
MX342326B
(es)
|
2011-09-27 |
2016-09-26 |
Novartis Ag |
3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
|
DK2760860T3
(en)
|
2011-09-28 |
2017-02-27 |
Euro Celtique Sa |
NITROGEN MUSTARD DERIVATIVES
|
WO2013053045A1
(en)
|
2011-10-12 |
2013-04-18 |
Beta Pharma Canada Inc. |
Heterocyclic molecules as apoptosis inducers
|
US8940737B2
(en)
|
2011-10-14 |
2015-01-27 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
WO2013062943A1
(en)
|
2011-10-24 |
2013-05-02 |
Glaxosmithkline Intellectual Property Development Limited |
New compounds
|
GB201118654D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
GB201118675D0
(en)
|
2011-10-28 |
2011-12-14 |
Astex Therapeutics Ltd |
New compounds
|
WO2013067277A1
(en)
|
2011-11-03 |
2013-05-10 |
Genentech, Inc. |
Alkylated piperazine compounds as inhibitors of btk activity
|
EP2773360B1
(en)
|
2011-11-03 |
2018-02-28 |
Millennium Pharmaceuticals, Inc. |
Administration of nedd8-activating enzyme inhibitor and hypomethylating agent
|
AU2012335665A1
(en)
|
2011-11-10 |
2014-07-03 |
Memorial Sloan-Kettering Cancer Center |
Treatment of ovarian cancer with 2-amino-4H-naphtho[1,2-B]pyran-3-carbonitriles
|
JP2015501792A
(ja)
|
2011-11-10 |
2015-01-19 |
メモリアル スローン−ケタリング キャンサー センター |
ベンジリデンベンゾヒドラジドを用いた卵巣がんの治療
|
AU2012336154B2
(en)
|
2011-11-11 |
2017-01-12 |
Eli Lilly And Company |
Combination therapy for ovarian cancer
|
CN104302292A
(zh)
|
2011-11-22 |
2015-01-21 |
德西费拉制药有限责任公司 |
表现出抗癌和抗增殖活性的吡啶酮酰胺以及类似物
|
US9376469B2
(en)
|
2011-12-21 |
2016-06-28 |
New York University |
Proteolytically resistant hydrogen bond surrogate helices
|
JP6088542B2
(ja)
|
2012-01-10 |
2017-03-01 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH |
Aktキナーゼ阻害剤としての置換イミダゾピラジン類
|
WO2013107405A1
(en)
|
2012-01-19 |
2013-07-25 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
CN110711188A
(zh)
*
|
2012-01-20 |
2020-01-21 |
德玛公司 |
经取代的己糖醇类用于治疗恶性肿瘤的用途
|
LT2810937T
(lt)
|
2012-01-31 |
2017-02-10 |
Daiichi Sankyo Company, Limited |
Piridono darinys
|
TWI573792B
(zh)
|
2012-02-01 |
2017-03-11 |
歐陸斯迪公司 |
新穎治療劑
|
AU2013229995B2
(en)
|
2012-03-06 |
2017-04-13 |
Cephalon, Inc. |
Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor
|
WO2013138665A1
(en)
|
2012-03-16 |
2013-09-19 |
Sanford-Burnham Medical Research Institute |
Inhibitors of furin and other pro-protein convertases
|
EP2827901B1
(en)
|
2012-03-20 |
2017-09-06 |
Novartis AG |
Combination therapy of a mek inhibitor and an igf1r inhibitor
|
EA026412B1
(ru)
|
2012-03-30 |
2017-04-28 |
Ризен Фармасьютикалз Са |
НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ c-MET ПРОТЕИНКИНАЗ
|
US10280168B2
(en)
|
2012-03-30 |
2019-05-07 |
Agency For Science, Technology And Research |
Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
|
WO2013152301A1
(en)
|
2012-04-05 |
2013-10-10 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
O-glycan pathway ovarian cancer signature
|
EP2836482B1
(en)
|
2012-04-10 |
2019-12-25 |
The Regents of The University of California |
Compositions and methods for treating cancer
|
WO2013170115A1
(en)
|
2012-05-11 |
2013-11-14 |
Abbvie Inc. |
Pyridazine and pyridine derivatives as nampt inhibitors
|
US8921367B2
(en)
|
2012-05-31 |
2014-12-30 |
Amgen Inc. |
Use of AMG 900 for the treatment of cancer
|
US8461179B1
(en)
|
2012-06-07 |
2013-06-11 |
Deciphera Pharmaceuticals, Llc |
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
|
US8980934B2
(en)
|
2012-06-22 |
2015-03-17 |
University Health Network |
Kinase inhibitors and method of treating cancer with same
|
SG10201610869TA
(en)
*
|
2012-06-26 |
2017-02-27 |
Del Mar Pharmaceuticals |
Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalacti
|
WO2014009319A1
(en)
|
2012-07-11 |
2014-01-16 |
Boehringer Ingelheim International Gmbh |
Indolinone derivatives anticancer compounds
|
WO2014078295A1
(en)
|
2012-11-13 |
2014-05-22 |
BoYen Therapeutics, Inc. |
Gemcitabine prodrugs and uses thereof
|
AR093445A1
(es)
|
2012-11-14 |
2015-06-10 |
Regeneron Pharma |
Metodos para tratar el cancer de ovario con antagonistas de dll4
|
US8946246B2
(en)
|
2012-11-16 |
2015-02-03 |
New Mexico Technical Research Foundation |
Synthetic rigidin analogues as anticancer agents, salts, solvates and prodrugs thereof, and method of producing same
|
CA2894399A1
(en)
|
2012-12-06 |
2014-06-12 |
Quanticel Pharmaceuticals, Inc. |
Histone demethylase inhibitors
|
CA2895504A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
CA2895808A1
(en)
|
2012-12-21 |
2014-06-26 |
Quanticel Pharmaceuticals, Inc. |
Histone demethylase inhibitors
|
WO2014100730A1
(en)
|
2012-12-21 |
2014-06-26 |
Epizyme, Inc. |
Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
|
SG11201506243XA
(en)
|
2013-02-14 |
2015-09-29 |
Bristol Myers Squibb Co |
Tubulysin compounds, methods of making and use
|
JP2016516701A
(ja)
|
2013-03-11 |
2016-06-09 |
アッヴィ・インコーポレイテッド |
縮合四環系ブロモドメイン阻害剤
|
EP2970268A1
(en)
|
2013-03-13 |
2016-01-20 |
AbbVie Inc. |
Cdk9 kinase inhibitors
|
EP2970288A1
(en)
|
2013-03-15 |
2016-01-20 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
JP2016512239A
(ja)
|
2013-03-15 |
2016-04-25 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Atrキナーゼの阻害剤として有用な化合物
|
US10413538B2
(en)
|
2013-05-08 |
2019-09-17 |
Bionumerik Pharmaceuticals, Inc. |
Administration of karenitecin for the treatment of platinum and/or taxane chemotherapy-resistant or -refractory advanced ovarian cancer
|
US20140371158A1
(en)
|
2013-06-14 |
2014-12-18 |
Georgia Regents University |
Beauvericin compositions and methods thereof for inhibiting the hsp90 chaperone pathway
|
AU2014100435A4
(en)
|
2013-06-17 |
2014-05-29 |
Macau University Of Science And Technology |
A novel treatment of Gefitinib-resistant non-small-cell lung cancer
|
MX2015018038A
(es)
|
2013-07-03 |
2016-03-16 |
Hoffmann La Roche |
Compuestos de heteroaril-piridona y aza-piridona-amida.
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
US9249151B2
(en)
|
2013-08-23 |
2016-02-02 |
Boehringer Ingelheim International Gmbh |
Bis-amido pyridines
|
US9278978B2
(en)
|
2013-08-23 |
2016-03-08 |
Boehringer Ingelheim International Gmbh |
6-Alkynyl Pyridine
|
US20150065526A1
(en)
|
2013-09-05 |
2015-03-05 |
Emory University |
Overcoming acquired resistance to chemotherapy treatments through suppression of stat3
|
US8927717B1
(en)
|
2014-02-14 |
2015-01-06 |
National Defense Medical Center |
Thiochromeno[2,3-c]quinolin-12-one derivatives, preparation method and application thereof
|